| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Research |
1 Laboratoire de Génétique Moléculaire-Institut National de la Sante et de la Recherche Medicale U745, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris V; 2 Département de Génétique, Hôpital de la Pitié-Salpêtrière, Paris, France; and 3 Laboratoire d'Oncogénétique-Institut National de la Sante et de la Recherche Medicale U735, Centre René Huguenin, St-Cloud, France
Requests for reprints: Ivan Bièche, Laboratoire de Génétique Moléculaire-Institut National de la Sante et de la Recherche Medicale U745, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris 5, 4 Avenue de l'Observatoire, 75006 Paris, France. Phone: 33-1-53-73-97-25; Fax: 33-1-44-07-17-54; E-mail: ivan.bieche{at}univ-paris5.fr.
We have previously detected a large germ-line deletion, which included the entire p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster, in the largest melanoma-neural system tumor (NST) syndrome family known to date by means of heterozygosity mapping based on microsatellite markers. Here, we used gene dose mapping with sequence-tagged site real-time PCR to locate the deletion end points, which were then precisely characterized by means of long-range PCR and nucleotide sequencing. The deletion was exactly 403,231 bp long and included the entire p15/CDKN2B, p16/CDKN2A, and p14/ARF genes. We then developed a simple and rapid assay to detect the junction fragment and to serve as a direct predictive DNA test for this large French family. We identified a new large antisense noncoding RNA (named ANRIL) within the 403-kb germ-line deletion, with a first exon located in the promoter of the p14/ARF gene and overlapping the two exons of p15/CDKN2B. Expression of ANRIL mainly coclustered with p14/ARF both in physiologic (various normal human tissues) and in pathologic conditions (human breast tumors). This study points to the existence of a new gene within the p15/CDKN2B-p16/CDKN2A-p14/ARF locus putatively involved in melanoma-NST syndrome families and in melanoma-prone families with no identified p16/CDKN2A mutations as well as in somatic tumors. [Cancer Res 2007;67(8):39639]
This article has been cited by other articles:
![]() |
N. J. Samani, O. T. Raitakari, K. Sipila, M. D. Tobin, H. Schunkert, M. Juonala, P. S. Braund, J. Erdmann, J. Viikari, L. Moilanen, et al. Coronary Artery Disease-Associated Locus on Chromosome 9p21 and Early Markers of Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1679 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Peters Tumor Suppression for ARFicionados: The Relative Contributions of p16INK4a and p14ARF in Melanoma J Natl Cancer Inst, June 4, 2008; 100(11): 757 - 759. [Full Text] [PDF] |
||||
![]() |
H. M. Broadbent, J. F. Peden, S. Lorkowski, A. Goel, H. Ongen, F. Green, R. Clarke, R. Collins, M. G. Franzosi, G. Tognoni, et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p Hum. Mol. Genet., March 15, 2008; 17(6): 806 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Talmud, J. A. Cooper, J. Palmen, R. Lovering, F. Drenos, A. D. Hingorani, and S. E. Humphries Chromosome 9p21.3 Coronary Heart Disease Locus Genotype and Prospective Risk of CHD in Healthy Middle-Aged Men Clin. Chem., March 1, 2008; 54(3): 467 - 474. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |